Entrada Therapeutics Ownership | Who Owns Entrada Therapeutics?


OverviewForecastRevenueFinancialsChart

Entrada Therapeutics Ownership Summary


Entrada Therapeutics is owned by 20.58% institutional investors, 12.24% insiders, and 67.18% retail investors. Baker bros. advisors lp is the largest institutional shareholder, holding 11.77% of TRDA shares. US Small-Cap Growth II Equity Comp is the top mutual fund, with 4.01% of its assets in Entrada Therapeutics shares.

TRDA Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockEntrada Therapeutics20.58%12.24%67.18%
SectorHealthcare Stocks 42.54%10.83%46.63%
IndustryBiotech Stocks 45.22%10.75%44.04%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Baker bros. advisors lp4.87M11.77%$28.22M
Mpm asset management4.38M10.60%$25.41M
5am venture management4.26M10.30%$24.69M
Janus henderson group2.08M5.12%$36.01M
Blackrock1.69M5.06%$24.14M
Blackrock funding, inc. /de2.04M4.94%$11.86M
Vanguard group1.60M3.88%$9.30M
Wellington management group llp954.42K2.31%$5.54M
Stepstone group lp761.28K1.84%$4.42M
Geode capital management645.12K1.56%$3.74M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Mpm asset management4.38M57.09%$25.41M
5am venture management4.26M9.04%$24.69M
Stepstone group lp761.28K2.08%$4.42M
Corton capital38.85K0.55%$225.32K
Nan fung group49.08K0.48%$284.68K
Baker bros. advisors lp4.87M0.20%$28.22M
Tcg crossover management584.96K0.17%$3.39M
Oxford asset management llp29.16K0.06%$169.13K
Sherbrooke park advisers18.57K0.05%$107.72K
Cantor fitzgerald, l. p.67.33K0.03%$3.91M

Top Buyers

HolderShares% AssetsChange
Janus henderson group2.08M0.02%368.91K
Acadian asset management297.94K0.00%252.14K
Renaissance594.30K0.00%214.80K
Blackrock1.69M0.00%207.70K
Jane street group247.52K0.00%196.36K

Top Sellers

HolderShares% AssetsChange
Price t rowe associates inc /md/360.53K0.00%-2.21M
Redmile group---560.97K
Fmr31.95K--464.18K
Wellington management group llp954.42K0.00%-106.30K
Arrowstreet capital, limited partnership---102.01K

New Positions

HolderShares% AssetsChangeValue
Jacobs levy equity management134.24K0.01%134.24K$1.91M
Algert global129.81K0.01%129.81K$753.00K
Cubist systematic strategies122.68K0.00%122.68K$711.52K
Two sigma investments, lp93.19K0.00%93.19K$540.52K
Xtx topco93.08K0.03%93.08K$539.86K

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-4.00
Amundi-12.00
Parallel advisors-16.00
Rothschild investment-20.00
Advantage alpha capital partners lp-20.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202562-38.00%8,507,595-70.84%200.41%35-44.44%20-4.76%
Jun 30, 2025105-4.55%29,576,02637.87%712.62%6637.50%23-45.24%
Mar 31, 20251105.77%30,175,230-1.40%731.29%46-25.81%4282.61%
Dec 31, 202462-38.61%9,425,072-68.69%230.42%37-43.08%13-27.78%
Sep 30, 202410121.69%30,100,5701.46%740.98%6512.07%1863.64%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
US Small-Cap Growth II Equity Comp1.52M4.01%-163.10K
T. Rowe Price New Horizons1.37M3.59%-157.39K
Vanguard Total Stock Mkt Idx Inv932.09K2.45%-20.55K
iShares Russell 2000 ETF660.85K1.74%-
Fidelity Growth Compy Commingled Pl O561.18K1.51%-
T. Rowe Price New Horizons Tr-A459.17K1.21%7.79K
T. Rowe Price New Horizons Tr-Z451.38K1.20%649.00
Fidelity Small Cap Index279.69K0.74%29.61K
Vanguard Institutional Extnd Mkt Idx Tr255.86K0.67%-116.59K
iShares Russell 2000 Value ETF243.94K0.64%-

Recent Insider Transactions


DateNameRoleActivityValue
Nov 21, 2025WENTWORTH KORY JAMES Chief Financial OfficerSell$88.93K
Nov 20, 2025BAKER BROS. ADVISORS LP-Buy$118.69K
Nov 20, 2025BAKER BROS. ADVISORS LP-Buy$121.39K
Nov 20, 2025BAKER BROS. ADVISORS LP-Buy$10.76K
Nov 20, 2025BAKER BROS. ADVISORS LP-Buy$11.00K

Insider Transactions Trends


DateBuySell
2025 Q412-
2025 Q3-8
2025 Q2-8
2025 Q1-1
2024 Q4-17

TRDA Ownership FAQ


Who Owns Entrada Therapeutics?

Entrada Therapeutics shareholders are primarily institutional investors at 20.58%, followed by 12.24% insiders and 67.18% retail investors. The average institutional ownership in Entrada Therapeutics's industry, Biotech Stocks , is 45.22%, which Entrada Therapeutics falls below.

Who owns the most shares of Entrada Therapeutics?

Entrada Therapeutics’s largest shareholders are Baker bros. advisors lp (4.87M shares, 11.77%), Mpm asset management (4.38M shares, 10.60%), and 5am venture management (4.26M shares, 10.30%). Together, they hold 32.66% of Entrada Therapeutics’s total shares outstanding.

Does Blackrock own Entrada Therapeutics?

Yes, BlackRock owns 5.06% of Entrada Therapeutics, totaling 1.69M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 24.14M$. In the last quarter, BlackRock increased its holdings by 207.7K shares, a 13.98% change.

Who is Entrada Therapeutics’s biggest shareholder by percentage of total assets invested?

Mpm asset management is Entrada Therapeutics’s biggest shareholder by percentage of total assets invested, with 57.09% of its assets in 4.38M Entrada Therapeutics shares, valued at 25.41M$.

Who is the top mutual fund holder of Entrada Therapeutics shares?

US Small-Cap Growth II Equity Comp is the top mutual fund holder of Entrada Therapeutics shares, with 4.01% of its total shares outstanding invested in 1.52M Entrada Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools